No internet connection — showing the saved version of the page.

Organon & Co

USUSD
← to the screener
US:OGNLSE:0A9W

Organon & Co (LSE:0A9W) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
organon.com
Investor relations
organon.com/investor-relations/
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
Oss, United States
CEO
Joseph T. Morrissey
Employees
10 000
Founded
1923
Shares outstanding
262.61 M as of 2026-07-24
Year: +1.0% · 3 years: +2.8% · 5 years: +3.6% (excluding splits)
DateSharesChange
24.07.2026262.61 M—no significant change
27.04.2026262.6 M+0.9%issuance (dilution)
17.02.2026260.32 M+0.1%issuance (dilution)
03.11.2025259.98 M—no significant change
30.07.2025259.97 M—no significant change
25.04.2025259.96 M+0.8%issuance (dilution)
25.02.2025257.95 M+0.2%issuance (dilution)
25.10.2024257.54 M+0.03%no significant change
30.07.2024257.47 M+0.1%issuance (dilution)
26.04.2024257.17 M+0.6%issuance (dilution)
20.02.2024255.64 M+0.01%no significant change
27.10.2023255.61 M+0.01%no significant change
04.08.2023255.57 M+0.2%issuance (dilution)
28.04.2023255.06 M+0.3%issuance (dilution)
22.02.2023254.38 M—no significant change
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
242.99 M
Market cap
3.6 B USD
Insiders
0.46%
Institutions
84.8%
Industry (SIC)
Pharmaceutical Preparations
ISIN
US68622V1061
LEI
549300AMCKY57OK2CO56
Payout ratio
8.6%
FCF
567 M USD
Payout / FCF
3%
Debt
8.55 B USD
13 y of FCF
Dividend streak
5 y
Earnings, FCF and dividends paid — for the 12 months to 30.06.2026 (the company's latest report).
NAV
3.83 USD · P/NAV 3.58
Balance sheet date30.06.2026
Assets13.2 B USD
− Liabilities12.2 B USD
= NAV (equity of the company's shareholders)1.01 B USD
− Goodwill4.15 B USD
− Intangible assets1.11 B USD
= Tangible NAV−4.26 B USD
Shares262 609 000
NAV per share3.83 USD
Tangible NAV per share−16.22 USD
Share price (0A9W)13.7300 USD
P/NAV3.58
NAV history
Balance sheet dateNAVNAV per share
30.06.20261.01 B USD3.83 USD
31.03.2026903 M USD3.44 USD
31.12.2025752 M USD2.89 USD
30.09.2025906 M USD3.48 USD
30.06.2025733 M USD2.82 USD
31.03.2025542 M USD2.10 USD
31.12.2024472 M USD1.83 USD
30.09.2024493 M USD1.91 USD
Description

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksOGN primaryUSD13.74 -0.22%common stock
LSE London Stock Exchange0A9W IOBUSD13.73 +0.07%common stock

Price for 3 months

up day down day dividend ex-date payment dateHover / tap a day — open, close, high and low prices

Dividends

Per year, LSE:0A9W: 0.08 USD (4 paym.)

Organon & Co (0A9W) pays dividends quarterly. Per year (12 months up to and including the latest announced payment): 0.08 USD per share (payments: 4). That is about 0.58% of the current share price. Based on payment history, the next ex-dividend date is expected around 17.11.2026. Uninterrupted dividend history: 5 years.

Ex-datePaymentAmount%TypeTicker
2026-08-142026-09-100.0200 USD0.1/0.6 %quarterlyLSE:0A9W
2026-05-112026-06-110.0200 USD0.2/0.6 %quarterlyLSE:0A9W
2026-02-232026-03-120.0200 USD0.3/1.0 %quarterlyLSE:0A9W
2025-11-202025-12-110.0200 USD0.3/4.6 %quarterlyLSE:0A9W
2025-08-152025-09-110.0200 USD0.2/6.5 %quarterlyLSE:0A9W
2025-05-122025-06-120.0200 USD0.2/9.7 %quarterlyLSE:0A9W
2025-02-212025-03-130.2800 USD1.8/7.2 %quarterlyLSE:0A9W
2024-11-122024-12-120.2800 USD1.5/6.0 %quarterlyLSE:0A9W
2024-08-162024-09-120.2800 USD1.5/6.0 %quarterlyLSE:0A9W
2024-05-102024-06-130.2800 USD1.5/6.0 %quarterlyLSE:0A9W
2024-02-232024-03-140.2800 USD1.5/6.0 %quarterlyLSE:0A9W
2023-11-102023-12-140.2800 USD2.4/9.8 %quarterlyLSE:0A9W
2023-08-17—0.2800 USD1.2/4.9 %quarterlyLSE:0A9W
2023-05-12—0.2800 USD1.3/5.3 %quarterlyLSE:0A9W
2023-02-24—0.2800 USD1.1/4.2 %quarterlyLSE:0A9W
2022-11-10—0.2800 USD1.2/4.7 %quarterlyLSE:0A9W
2022-08-12—0.2800 USD0.9/3.5 %quarterlyLSE:0A9W
2022-05-13—0.2800 USD0.8/2.4 %quarterlyLSE:0A9W
2022-02-25—0.2800 USD0.8/1.6 %quarterlyLSE:0A9W
2021-11-19—0.2800 USD0.9/0.9 %quarterlyLSE:0A9W

Top holders

HolderStakeSharesReport date
Blackrock Inc.12.21%32.06 M2026-06-30
Pentwater Capital Manage…6.89%18.1 M2026-06-30
iShares Trust-iShares Co…6.09%16 M2026-08-31
Vanguard Portfolio Manag…5.76%15.13 M2026-06-30
Vanguard Capital Managem…4.54%11.91 M2026-06-30
State Street Corporation3.68%9.66 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%8.33 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.29%6.02 M2026-06-30
Goldman Sachs Group Inc1.98%5.2 M2026-06-30
UBS Group AG1.85%4.86 M2026-06-30
Geode Capital Management…1.83%4.82 M2026-06-30
Alliancebernstein L.P.1.81%4.75 M2026-06-30
Man Group PLC1.59%4.18 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.45%3.82 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%3.01 M2026-06-30
NexPoint Funds I-NexPoin…1.03%2.71 M2026-06-30
SPDR SERIES TRUST-State…0.94%2.47 M2026-08-31
iShares Trust-iShares S&…0.89%2.35 M2026-08-31
SPDR SERIES TRUST-State…0.54%1.41 M2026-08-31
Fidelity Concord Street…0.49%1.3 M2026-07-31
ALI KEVIN (Chief Executi…≈0.11%282 7312025-05-05
WALSH MATTHEW M (Chief F…≈0.08%212 7462026-03-31
MORRISSEY JOSEPH T JR (C…≈0.05%123 1232026-03-31
STAHLER RACHEL A (Chief…≈0.04%116 1052026-03-31
FALCIONE AARON (Officer)≈0.04%101 4312026-03-31
WEAVER KIRKE (General Co…≈0.04%92 6392026-03-31
NISITA VITTORIO (Officer…≈0.03%70 6192026-03-31
KARP DANIEL (Officer)≈0.03%69 5472026-03-31
HOLZBAUR LYNETTE (Office…≈0.02%52 8502026-05-06
COX CARRIE SMITH (Office…——2025-11-12